Clinical Trials Browser

Recruiting × INDUSTRY × Lenalidomide × Clear all

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Multiple Myeloma

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Multiple Myeloma, Neoplasms

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Recurrence

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Follicular

Multiple Myeloma, Recurrence

Lymphoma, B-Cell, Marginal Zone

Advanced Solid Tumor

Multiple Myeloma

Hematologic Neoplasms

Multiple Myeloma

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Multiple Myeloma

Clinical Trials

MAHOGANY

DREAMM-10

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

MagnetisMM-6

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

A Study of Daratumumab

MajesTEC-7

OLYMPIA-5

EPCORE™FL-2

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

PLYCOM

GLOBRYTE

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

SIDNEY

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

STOMP

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients